

5.4.3 - Appendix 3 – New policies in development, at validation, proposed and on hold (62)

Ref No	Name	Type	Commissioning Team	Purpose	Status
SS143	Complex Spinal Surgery	Service Specification	Neurosciences and Complex Conditions	Prompted by the work being carried out by the collaborative on spinal surgery	In development
PPS153	Complex Obesity Surgery (Children) for severe and Complex Obesity	Policy Position	Women and Children	Not funded following CIAG in 2017/18 but subsequently approved by JC	In development
CP165	Targeted Therapies for the Treatment of Pulmonary Hypertension in Adults	Commissioning Policy	Cardiac	Development of a dedicated NWJCC policy. To date we have been using the NHS England policy.	In development
CP170	Cryopreservation of Gametes	Commissioning Policy	Women and Children	Development of a dedicated NWJCC policy.	On hold
SS171	Paediatric Surgery	Service Specification	Women and Children	Identified as a gap in NWJCC portfolio of service specifications	In development
SS180	Prolonged Disorders of Consciousness	Service Specification	Neurosciences and Complex Conditions	Development of a dedicated NWJCC policy.	On hold
SS190	Neonatal Transportation	Service Specification	Women and Children	Development of a dedicated NWJCC policy	On hold

CP192	Percutaneous Patent Foramen Closures (PPFOC)	Commissioning Policy	Cardiac	Development of a dedicated NWJCC policy	Proposed -not started
SS194	Cystic Fibrosis (Children)	Service Specification	Cardiac	Development of a dedicated NWJCC policy	In development
SS200	Cardiac Transplantation	Service Specification	Cardiac	Development of a dedicated NWJCC policy	On hold
SS202	High Consequence Infectious Diseases, Specialist Isolation	Service Specification	Which team?	Development of a dedicated NWJCC policy	In development
CP204	Inherited Metabolic Disease	Commissioning Policy	Neurosciences and Complex Conditions	Development of a dedicated NWJCC policy	In development
SS207	Inherited Cardiac Conditions	Service Specification	Cardiac	Development of a dedicated NWJCC policy	In development
CP210	Intestinal Failure	Commissioning Policy	Neurosciences and Long-term conditions	Development of a dedicated NWJCC policy	In development
SS210	Intestinal Failure	Service Specification	Neurosciences and Long-term conditions	Development of a dedicated NWJCC policy	In development
SS216	Lymphoma Pathology	Service Specification	Cancer and Blood	Development of a dedicated NWJCC policy	On hold
PPS225	Allogeneic HSCT for Primary Immunodeficiencies	Policy Position	Cancer and Blood	Development of a dedicated NWJCC policy	At validation

SS231	Specialised Paediatric ENT	Service Specification	Women and Children	Development of a dedicated NWJCC policy	On hold
PPS242	Percutaneous patent foramen ovale closure for the prevention of recurrent cerebral embolic stroke in adults (around age 60 years and under)	Policy Position	Cardiac	Development of NICE Technology appraisal guidance	In development
SS243	Pulmonary Hypertension Centre - Shared Care (Adults)	Service Specification	Cardiac	Development of a dedicated NWJCC policy	Policy no longer aligned with the proposed satellite service. Policy being revised.
SS246	Specialist Mesothelioma Multi-Disciplinary Team	Service Specification	Cancer and Blood	Development of a dedicated NWJCC policy	On hold
PPS255	Roxadustat for treating symptomatic anaemia in chronic kidney disease	Policy Position	Renal	Development of NICE technology guidance (TA807)	In development
PPS256	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	Policy Position	Renal	Development of NICE technology guidance (TA809)	In development
PPS260	Atypical haemolytic uraemic syndrome (aHUS) (Eculizumab & Ravulizumab)	Policy Position	Cancer and Blood	Development of NICE highly specialised technology guidance	In development
CP264	Nitisinone for the treatment of adult patients with alkaptonuria	Commissioning Policy	Neurosciences and Long-term Conditions	Development of AWMSG guidance	At validation

CP268	Paediatric Rehabilitation	Commissioning Policy	Women and Children	Development of a dedicated NWJCC policy	In development
SS268	Paediatric Rehabilitation	Service Specification	Women and Children	Development of a dedicated NWJCC policy	In development
CP269	Paediatric Oncology	Commissioning Policy	Women and Children	Development of a dedicated NWJCC policy	In development
SS270	Skin Camouflage	Service Specification	Mental Health & Vulnerable Groups	Development of a dedicated NWJCC policy	In development
CP275	Specialised Paediatric Respiratory	Commissioning Policy	Women and Children	Development of a dedicated NWJCC policy	On hold
SS275	Specialised Paediatric Respiratory	Service Specification	Women and Children	Development of a dedicated NWJCC policy	On hold
CP276	Paediatric Infectious Diseases	Commissioning Policy	Woman and Children	Development of a dedicated NWJCC policy	In development
SS276	Paediatric Infectious Diseases	Service Specification	Women and children	Development of a dedicated NWJCC policy	In development
SS287	Acute Myeloid Leukaemia (AML) immunophenotyping	Service Specification	Cancer and Blood	Part of haematology review project	At validation
SS288	All Wales Acute Myeloid Leukaemia MDT	Service Specification	Cancer and Blood	Part of haematology review project	At validation

CP289	Gender Identity Services for Adults (Surgical Interventions)	Commissioning Policy	Mental Health	Development of a dedicated NWJCC policy	In development
PPS292	Ruxolitinib for Acute Graft Versus Host Disease	Policy Position	Cancer and Blood		In development
PPS294	ECMO for respiratory failure in adults	Policy Position	Cancer and Blood		In development
PPS301	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	Policy Position Statement	Women and Children	NICE TA 949	In development
PPS303	Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	Policy Position Statement	Women and Children	Based on NICE guidance TA977	In development
PPS304	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (adults)	Policy Position Statement	Cancer and Blood	Based on NICE TA989	In development
PPS305	Exagamglogene autotemcel for treating transfusion dependent beta-thalassaemia	Policy Position Statement	Cancer and Blood	NICE final draft guidance published 08/08/2024. NICE TA1003 published 11 September	In development
SS309	Tier 4 Forensic Child and Adolescent Mental Health Service, Forensic Adolescent Consultation Service - Youth Justice Services	Service Specification	Mental Health and Vulnerable Groups		On hold

SS310	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis (SSAS)	Service Specification	Cardiac		In development
PPS314	Rituximab for treatment of acute thrombotic thrombocytopenic purpura (TTP)	Policy Position Statement	Cancer and Blood	NHS England » Rituximab for the treatment in acute Thrombotic Thrombocytopenic Purpura (TTP) and elective therapy to prevent TTP relapse At prioritisation in 2024	On hold
PPS315	Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours	Policy Position Statement	Women and Children	NICE TA1034 published 22 Jan 2025	In development
SS316	Specialised Paediatric Ophthalmology	Service Specification	Women and Children		In development
PPS317	Belimumab for treating active autoantibody-positive systemic lupus erythematosus in people aged 5-17 years	Policy Position Statement	Women and Children	NICE TA752. 5-17 years age range. NWJCC only commissioning in paediatrics	In development
PPS318	Clinical Neurophysiology (all ages)	Service Specification	Neurosciences and Long-term Conditions	NWJCC commissioning this service from 1 April 2025	In development

PPS319	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE TA1044 published 26 February 2025	In development
PPS320	Lisocabtagene maraleucl for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable	Policy Position Statement	Cancer and Blood	NICE TA1048 published 26 March 2025	In development
PPS321	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	Policy Position Statement	Women and Children	NICE TA1038 published 12 February 2025	In development
PPS322	Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over	Policy Position Statement	Women and Children	NICE TA1031 published 16 January 2025	In development
PPS323	Talimogene laherparepvec for treating unresectable metastatic melanoma	Policy Position Statement	Cancer and Blood	NICE TA410 published 28 September 2016	In development
SS324	Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke	Service Specification	Neurosciences and Long-term Conditions	Service specification to sit alongside CP168 commissioning policy	In development
CP325	Home Therapies Service for Adults requiring dialysis	Commissioning Policy	Welsh Kidney Network		In development
SS326	Home Therapies Service for Adults requiring dialysis	Service Specification	Welsh Kidney Network		In development

PPS327	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over	Policy Position Statement	Cancer and Blood	NICE TA1051 published 2 April 2025	In development
PPS328	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	Policy Position Statement	Neurosciences and Long-term Conditions	NICE HST 33 published 23 April 2025	In development
PPS329	Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over	Policy Position Statement	Cancer and Blood	NICE ID6342	In development
SS330	Electronic Assistive Technology (EAT)	Service Specification	Neurosciences and Long-term Conditions		In development
SS331	Online Digital Mental Health Therapies		Mental Health and Vulnerable Groups		In development